UK markets close in 5 hours 7 minutes

GILEAD SCIENCES DL-,001 (GIS.DU)

Dusseldorf - Dusseldorf Delayed price. Currency in EUR
Add to watchlist
58.17-0.59 (-1.00%)
As of 12:01PM CEST. Market open.
Full screen
Previous close58.76
Open58.99
Bid58.11 x 0
Ask58.46 x 0
Day's range57.93 - 58.32
52-week range46.22 - 61.15
Volume115
Avg. volume18
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Editor's pick
    Yahoo Finance Video

    We must move towards vaccine mandates to get ahead of Covid-19: Doctor

    Dr. Anand Swaminathan, Emergency Medicine Physician in New Jersey, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.

  • Gilead Sciences (GILD) Beats Q2 Earnings and Revenue Estimates
    Zacks

    Gilead Sciences (GILD) Beats Q2 Earnings and Revenue Estimates

    Gilead (GILD) delivered earnings and revenue surprises of 6.25% and 1.14%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

  • Gilead's COVID-19 drug helps boost 2nd-quarter results as HIV sales dip
    Reuters

    Gilead's COVID-19 drug helps boost 2nd-quarter results as HIV sales dip

    (Reuters) -Gilead Sciences Inc on Thursday posted a higher-than-expected second-quarter profit, helped by strong demand for its COVID-19 antiviral treatment, Veklury, but sales of its flagship HIV drugs lagged as the pandemic continued to limit visits to doctors. Sales of HIV medicines, which have stalled during the coronavirus pandemic, fell 2% to $3.9 billion. Gilead Chief Commercial Officer Johanna Mercier on a conference call with analysts said HIV sales in Europe have begun to recover, but U.S. demand has been slower.